Skip to content
Enveda: Finding Hidden Medicines in Nature episode artwork

Jun 4, 2026 53 min

Enveda: Finding Hidden Medicines in Nature

from Invest in Progress

The biotech company Enveda has developed a new approach to explore and ‘decode’ nature’s chemistry. Its goal is to discover molecules that could underpin a new generation of blockbuster drugs. In this podcast, the firm’s founder and chief executive, Viswa Colluru, explains how Enveda could become a trillion-dollar business, and Scottish Mortgage Investment Trust manager Tom Slater considers the risks and opportunities the company faces. Background: Scottish Mortgage first invested in Enveda in November 2024. The US-headquartered company uses a proprietary artificial intelligence (AI) large language model to discover and develop new medicines from natural sources. At the time of writing, it has a pipeline of 12 drug candidates in various stages of development that could form the basis of new therapies to treat dermatitis, obesity, inflammation and chronic pain. Enveda’s founder, Viswa Colluru, has reimagined the drug discovery process from first principles based on his insight that natural molecular compounds should have a better safety profile than engineered ones.“Healthcare is the biggest industry in the world, and if you can increase the odds of success in drug discovery, there are so many unmet needs that its opportunity is effectively unbounded,” says Scottish Mortgage manager, Tom Slater. Timecodes: 00:03 Coming up… 00:50 Introduction 02:49 Viswa Colluru interview begins 03:08 “Things that work in the lab [often] don’t work in people” 04:35 A mission grounded in a family death 08:50 Invested life savings 11:24 Picking up from where evolution left off 15:16 Using AI to make sense of nature 21:32 A chemistry-first approach 25:16 Historic points of failure 27:32 Reimagining drug discovery from first principles 29:19 Splitting work between US and India 32:19 A growing drug candidate pipeline 35:07 Partnering with Microsoft and Sanofi 38:19 The relationship with Recursion Pharmaceuticals 41:02 “Incredible people looking in unexpected places” 43:00 A globally loved pharma company 43:38 Tom Slater on the investment case 52:42 Podcast lookahead Please see our glossary of terms. Read the transcript. Check the podcast description to ensure this content is suitable for you. Your capital is at risk. Presenter: Claire Shaw Executive Producer: Leo Kelion Line producer: Jessica Rooney Broadcast Technician: Samual O’Hare Editors: Kerry Ingram

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Enveda: Finding Hidden Medicines in Nature

0:00 53:33

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Invest in Progress?

This episode is 53 minutes long.

When was this Invest in Progress episode published?

This episode was published on June 4, 2026.

Can I download this Invest in Progress episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.